Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | JUN | P05412 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11158875 | 0.88 | RAB9A (0.55) | RAB9AMAPTCYP2D6GRM8GRM4 | |
| SCHEMBL31032579 | 0.87 | ALDH1A1 (0.46) | RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10728788 | 0.87 | ALDH1A1 (0.46) | RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16309275 | 0.86 | GPR35 (0.55) | MAPTALDH1A1KDM4ETTRTDP1 | |
| SCHEMBL10751886 | 0.86 | RAB9A (0.53) | RAB9AMAPTCYP2D6GRM8GRM4 | |
| SCHEMBL7031564 | 0.84 | RAB9A (0.60) | RAB9AMAPTCYP2D6GRM8GRM4 | |
| SCHEMBL11154751 | 0.83 | RAB9A (0.51) | RAB9AMAPTCYP2D6GRM8GRM4 | |
| SCHEMBL8297049 | 0.83 | RAB9A (0.59) | RAB9AMAPTCYP2D6GRM8GRM4 | |
| SCHEMBL345717 | 0.83 | RAB9A (0.59) | RAB9AMAPTCYP2D6GRM8GRM4 | |
| SCHEMBL2913406 | 0.82 | LMNA (0.57) | MAPTCYP2D6ALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118388384-A | Organic selenium-propiophenone derivative and preparation method and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2024-07-26 | — | — | CN | disclosed |
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| EP-0101223-B1 | PROCESS FOR PRODUCING PHENYLACETONES | UBE INDUSTRIES, LTD. (JP) | 1987-04-01 | — | — | EP | disclosed |
| US-4638094-A | OXIDATION OF PROPYLENEBENZENES | UBE INDUSTRIES, LTD. (JP) | 1987-01-20 | — | — | US | disclosed |
| EP-0101223-A2 | Process for producing phenylacetones | UBE INDUSTRIES, LTD. (JP) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | RAB9A 1967/4885MAPT 3387/4885CYP2D6 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.